3,4-dihydroxyphenylacetaldehyde has been researched along with Parkinson Disease in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.41) | 18.2507 |
| 2000's | 7 (18.92) | 29.6817 |
| 2010's | 23 (62.16) | 24.3611 |
| 2020's | 5 (13.51) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, S; Ojika, M; Sugumaran, M; Tanaka, H; Wakamatsu, K | 1 |
| Goldstein, DS; Isonaka, R; Jinsmaa, Y; Sharabi, Y | 1 |
| Bellen, HJ; Duraine, L; Goldstein, DS; Kao, CY; Lee, HJ; Lin, SC; Tsai, MJ; Tsai, SY; Wang, L; Xu, M | 1 |
| Goldstein, DS | 1 |
| Acquasaliente, L; Bucciantini, M; Fongaro, B; Leri, M; Palazzi, L; Polverino de Laureto, P; Stefani, M | 1 |
| Diwakar, S; Melethadathil, N; Nair, B; Sasidharakurup, H | 1 |
| Aguirre, AL; Doorn, JA; Florang, VR; Murry, DJ; Vanle, BC | 1 |
| Goldstein, DS; Sharabi, Y | 1 |
| Bax, A; DuMond, JF; Levine, RL; Monti, S; Werner-Allen, JW | 1 |
| do Nascimento, LA; Eliezer, D; Follmer, C; Lima, VA | 1 |
| Burke, WJ; Gillespie, KN; Hsu, FF; Kumar, VB; Lakshmi, VM | 1 |
| Alter, S; Goldstein, DS; Holmes, C; Kopin, IJ; Mash, DC; Miller, GW; Sharabi, Y; Strong, R; Sullivan, P | 1 |
| Goldstein, DS; Kopin, IJ; Sharabi, Y | 1 |
| Casida, JE; Cooney, A; Ford, B; Goldstein, DS; Jinsmaa, Y; Sullivan, P | 1 |
| Goldstein, DS; Holmes, C; Kopin, IJ; Mash, DC; Sharabi, Y; Sullivan, P | 1 |
| Araujo, GD; Coelho-Cerqueira, E; Domont, GB; Eliezer, D; Follmer, C; Pinheiro, AS; Yatabe-Franco, DY | 1 |
| Goldstein, DS; Holmes, C; Jinsmaa, Y; Kopin, IJ; Sharabi, Y; Sullivan, P | 2 |
| Goldstein, DS; Heredia-Moya, J; Holmes, C; Whittaker, N | 1 |
| Basile, MJ; Goldstein, DS; Holmes, C; Kopin, IJ; Mash, DC; Sullivan, P | 1 |
| Burke, WJ; Galvin, JE; Gan, Q; Kumar, VB; Panneton, WM | 1 |
| Anderson, DG; Buettner, GR; Doorn, JA; Mariappan, SV | 1 |
| Barwina, M; Kaletha, K; Rybakowska, I; Sein Anand, J; Szreder, G; Waldman, W | 1 |
| Beausoleil, E; Kong, D; Kotraiah, V; Pallares, D; Toema, D | 1 |
| Fernandez, E; Goldstein, DS; Martinez, PA; Strong, R; Sullivan, P; Wey, MC | 1 |
| Doorn, JA; Florang, VR; Vermeer, LM | 1 |
| Barnhill, L; Bronstein, JM; Casida, JE; Cockburn, M; Fitzmaurice, AG; Lam, HA; Lulla, A; Maidment, NT; Murphy, NP; O'Donnell, KC; Rhodes, SL; Ritz, B; Sagasti, A; Stahl, MC | 1 |
| Burke, WJ | 1 |
| Burke, WJ; Li, SW; Nonneman, R; Williams, EA; Zahm, DS | 1 |
| Galvin, JE | 1 |
| Chung, HD; Hsu, FF; Mattammal, MB; Strong, R | 1 |
| Chung, HD; Haring, JH; Mattammal, MB; Raghu, G; Strong, R | 1 |
| Eisenhofer, G; Harvey-White, J; Kirk, K; Kopin, IJ; Lamensdorf, I; Nechustan, A | 1 |
| Brown, AM; Burke, WJ; Conway, AD; Jain, JC; Kristal, BS; Li, SW; Ulluci, PA | 1 |
| Burke, WJ; Li, SW; Lin, TS; Minteer, S | 1 |
| Hashimoto, T; Yabe-Nishimura, C | 1 |
6 review(s) available for 3,4-dihydroxyphenylacetaldehyde and Parkinson Disease
| Article | Year |
|---|---|
The "Sick-but-not-Dead" Phenomenon Applied to Catecholamine Deficiency in Neurodegenerative Diseases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Autonomic Nervous System Diseases; Dopamine; Humans; Lewy Body Disease; Norepinephrine; Parkinson Disease; Sympathetic Nervous System | 2020 |
The heart of PD: Lewy body diseases as neurocardiologic disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Catecholamines; Dopamine; Heart; Humans; Lewy Bodies; Lewy Body Disease; Multiple System Atrophy; Myocardium; Neuroimaging; Neurons; Parkinson Disease; Sympathetic Nervous System | 2019 |
Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Apoptosis; Catecholamines; Humans; Lipid Peroxidation; Neurodegenerative Diseases; Neurons; Oxidation-Reduction; Parkinson Disease | 2014 |
[Reactive oxygen species and 3,4-dihydroxyphenylacetaldehyde in pathogenesis of Parkinson disease].
Topics: 3,4-Dihydroxyphenylacetic Acid; Brain; Humans; Oxidative Stress; Parkinson Disease; Reactive Oxygen Species | 2011 |
3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Drug Delivery Systems; Humans; Neuroprotective Agents; Parkinson Disease | 2003 |
Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Dopamine; Humans; Oxidative Stress; Parkinson Disease; Substantia Nigra | 2006 |
31 other study(ies) available for 3,4-dihydroxyphenylacetaldehyde and Parkinson Disease
| Article | Year |
|---|---|
Oxidative Transformations of 3,4-Dihydroxyphenylacetaldehyde Generate Potential Reactive Intermediates as Causative Agents for Its Neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Neurotoxicity Syndromes; Oxidation-Reduction; Parkinson Disease | 2021 |
3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; alpha-Synuclein; Antioxidants; Cell Line; Copper; Dopamine; Humans; Monoamine Oxidase; Monophenol Monooxygenase; Oligodendroglia; Oxidation-Reduction; Parkinson Disease; Protein Binding; Protein Conformation; Tolcapone | 2020 |
Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson's disease through mitochondrial dysfunction.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Brain; Cell Line; Cell Line, Tumor; Cohort Studies; COUP Transcription Factor II; Datasets as Topic; Disease Models, Animal; Disease Progression; Dopaminergic Neurons; Female; Humans; Male; Mice; Mice, Knockout; Mitochondria; Oxidative Stress; Parkinson Disease; Primary Cell Culture; Rats; RNA-Seq; Up-Regulation | 2020 |
Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amyloid; Cell Proliferation; Dopamine; Dopaminergic Neurons; Humans; Oxidative Stress; Parkinson Disease; Phenylethyl Alcohol; Protein Aggregation, Pathological; Protein Multimerization | 2021 |
A Systems Model of Parkinson's Disease Using Biochemical Systems Theory.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Biomarkers; Brain; Cell Death; Computer Simulation; Disease Progression; Dopamine; Dopaminergic Neurons; Gene Expression Regulation; Humans; Models, Statistical; Neurofibrillary Tangles; Parkinson Disease; Reactive Oxygen Species; Signal Transduction; Stochastic Processes; Systems Theory; tau Proteins; Ubiquitin-Protein Ligases | 2017 |
Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Enzyme Induction; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Parkinson Disease; Protein Aggregates; Rabbits; Rats | 2017 |
Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Cross-Linking Reagents; Humans; Isoindoles; Models, Molecular; Neurons; Oxidation-Reduction; Parkinson Disease | 2018 |
Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylation; alpha-Synuclein; Dopamine; Dopaminergic Neurons; Humans; Membrane Lipids; Mutation; Oxidation-Reduction; Parkinson Disease; Protein Multimerization; Protein Processing, Post-Translational | 2019 |
Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; alpha-Synuclein; Animals; Indans; Neuroprotective Agents; Parkinson Disease; PC12 Cells; Rats | 2019 |
Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde Dehydrogenase, Mitochondrial; Animals; Brain Chemistry; Catechols; Dihydroxyphenylalanine; Dopamine; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Parkinson Disease; Putamen; Retinal Dehydrogenase; Vesicular Monoamine Transport Proteins | 2013 |
Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Aldehydes; Animals; Antifungal Agents; Benomyl; Cell Line; Enzyme Inhibitors; Humans; Lipid Peroxidation; Mice; Parkinson Disease; PC12 Cells; Rats | 2014 |
Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Aldehyde Dehydrogenase; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Female; Frontal Lobe; Humans; Male; Methoxyhydroxyphenylglycol; Multiple System Atrophy; Neurons; Norepinephrine; Parkinson Disease | 2015 |
Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amyloid; Animals; Cell Membrane; Dopamine; Dopaminergic Neurons; Humans; Lysine; Membrane Lipids; Oxidation-Reduction; Parkinson Disease; Rats; Schiff Bases; Substantia Nigra | 2015 |
Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopaminergic Neurons; Dose-Response Relationship, Drug; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; PC12 Cells; Rats | 2016 |
3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopamine Agents; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidation-Reduction; Parkinson Disease; PC12 Cells; Phenylethyl Alcohol; Rats | 2016 |
Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Chromatography, Liquid; Droxidopa; Drug Contamination; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Parkinson Disease | 2010 |
Catechols in post-mortem brain of patients with Parkinson disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Brain Chemistry; Dopamine; Female; Humans; Male; Parkinson Disease; Putamen | 2011 |
The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Dopamine; Glial Fibrillary Acidic Protein; Immunohistochemistry; Male; Microglia; Neurons; Parkinson Disease; Phenotype; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase | 2010 |
Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone.
Topics: 3,4-Dihydroxyphenylacetic Acid; Benzoquinones; Cyclooxygenase 2; Free Radicals; Humans; Oxidation-Reduction; Parkinson Disease | 2011 |
Natural toxin implicated as triggering Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Humans; Neurons; Neurotoxins; Parkinson Disease | 2011 |
Identification of aldehyde dehydrogenase 1A1 modulators using virtual screening.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde Dehydrogenase, Mitochondrial; Benzamides; Benzodioxoles; Binding Sites; Case-Control Studies; Enzyme Activation; Gene Expression Regulation, Enzymologic; Humans; Ligands; Molecular Docking Simulation; Parkinson Disease; Retinal Dehydrogenase; Small Molecule Libraries; Substantia Nigra; User-Computer Interface | 2013 |
Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Body Weight; Cognition Disorders; Cytosol; Disease Models, Animal; Dopamine; Female; Genotype; Male; Mice; Mice, Transgenic; Mitochondria; NAD; Neurodegenerative Diseases; Neurons; Parkinson Disease; Time Factors; Tyrosine 3-Monooxygenase | 2012 |
Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; Catechols; Cell Line; Chromatography, High Pressure Liquid; Dopaminergic Neurons; Flow Cytometry; Humans; Parkinson Disease; Structure-Activity Relationship; Tyrosine 3-Monooxygenase | 2012 |
Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Benomyl; Dopaminergic Neurons; Flow Cytometry; Fungicides, Industrial; Humans; Logistic Models; Mesencephalon; Mitochondria; Nerve Degeneration; Odds Ratio; Parkinson Disease; Rats; Zebrafish | 2013 |
3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glial Fibrillary Acidic Protein; Homovanillic Acid; Immunohistochemistry; Male; Neurons; Parkinson Disease; Phenylethyl Alcohol; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2003 |
Confirmation of a dopamine metabolite in parkinsonian brain tissue by gas chromatography-mass spectrometry.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Brain; Dopamine; Gas Chromatography-Mass Spectrometry; Humans; Molecular Structure; Monoamine Oxidase; Parkinson Disease; Substantia Nigra | 1993 |
An endogenous dopaminergic neurotoxin: implication for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Culture Techniques; Dopamine; Dopamine Uptake Inhibitors; gamma-Aminobutyric Acid; L-Lactate Dehydrogenase; Mesencephalon; Neostriatum; Nerve Endings; Parkinson Disease; PC12 Cells; Radioligand Assay; Rats; Synaptosomes | 1995 |
3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Dopamine; Energy Metabolism; Enzyme Inhibitors; Estrogens, Non-Steroidal; Fluorenes; Hydantoins; Isoflavones; Mitochondria; Neurons; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; PC12 Cells; Phenylethyl Alcohol; Rats; Rotenone | 2000 |
Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.
Topics: 3,4-Dihydroxyphenylacetic Acid; 4-Aminobenzoic Acid; Aminobenzoates; Animals; Aristolochic Acids; Cell Death; Cell Differentiation; Cyclosporine; Dopamine; Dopamine Antagonists; Enzyme Inhibitors; Ion Channels; Male; Membrane Proteins; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Nerve Growth Factor; para-Aminobenzoates; Parkinson Disease; PC12 Cells; Phenanthrenes; Rats; Rats, Inbred F344; Respiration; Rotenone; Trifluoperazine; Uncoupling Agents | 2001 |
3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aldehydes; Brain; Catechols; Humans; Hydrogen Peroxide; Hydroxyl Radical; Male; Nerve Degeneration; Parkinson Disease; Spectrophotometry, Atomic | 2001 |
Oxidative metabolite of dopamine, 3,4-dihydroxyphenylacetaldehyde, induces dopamine release from PC12 cells by a Ca2+-independent mechanism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Calcium; Calcium Channel Blockers; Dopamine; L-Lactate Dehydrogenase; Nifedipine; Oxidation-Reduction; Parkinson Disease; PC12 Cells; Rats | 2002 |